ESA Hyporesponsiveness Linked to Abnormal FGF23 Levels
In a study, hemodialysis patients with the highest and lowest FGF23 levels had higher risks for ESA hyporesponsiveness.
Kidney Week 2019
Novel Drug Eases Uremic Pruritus
In a phase 3 trial, difelikefalin, a kappa opioid receptor agonist, significant decreased itching and improved itching-related quality of life among dialysis patients suffering from pruritus.
Spironolactone Does Not Prevent Diabetic Nephropathy in Type 2 Diabetes
In a study, spironolactone treatment was not significantly better than placebo in preventing diabetic nephropathy in patients with high-risk type 2 diabetes.
Potassium Binder Found Effective Regardless of Hyperkalemia Severity
In a pooled analysis of data from 3 studies, patiromer lowered potassium levels into a target range of 3.8 to 5.0 mEq/L in 92.5% and 96.8% of patients with baseline potassium levels of 6.0 mEq/L or higher and less than 6.0 mEq/L, respectively.
Sepsis, Volume Overload Commonly Prompt CRRT
In a study, 43.8% of hospitalized patients had sepsis and 48.8% had fluid overload requiring continuous renal replacement therapy.
Parathyroidectomy May Offer Survival Edge in SHPT
In a study, patients with severe secondary hyperparathyroidism appeared to benefit the most from surgery.
Kidney Recovery Predictors in Dialysis-Requiring AKI Identified
Younger age, female sex, and lower serum creatinine are among the variables most strongly associated with recovery of kidney function following initiation of outpatient hemodialysis for acute kidney injury, a study found.
Higher Hyponatremia Risk Found With SSRIs
Users of selective serotonin reuptake inhibitors had a higher risk of hyponatremia than users of serotonin-norepinephrine reuptake inhibitors, especially with concurrent thiazide diuretic treatment.
Peripheral Artery Disease Linked to Intradialytic Hypotension
Intradialytic hypotension (IDH) occurring in 30% or more of hemodialysis sessions is associated with a 36% increased likelihood of peripheral artery disease compared with no IDH, according to a new study.
Stopping ACEi, ARB Therapy Ups Mortality in Chronic Kidney Disease
Discontinuing angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy more than doubles the risk of death and dialysis initiation, according to a new study.
Next post in Kidney Week 2019
